Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Refix ceiling price of...

    Refix ceiling price of Zydus rosuvastatin 20mg plus clopidogrel 75mg capsule: DoP orders NPPA

    Written by Ruby Khatun Khatun Published On 2018-06-09T13:41:42+05:30  |  Updated On 9 Jun 2018 1:41 PM IST
    Refix ceiling price of Zydus rosuvastatin 20mg plus clopidogrel 75mg capsule:  DoP orders NPPA

    New Delhi: The Department of Pharmaceuticals (DoP) has accepted the Zydus Healthcare’s review petition against price fixation of “Rosuvastatin 20mg + Clopidogrel 75mg Capsules” and has directed the NPPA to revise the ceiling prices of rosuvastatin 20mg plus clopidogrel 75mg capsules.


    Rosuvastatin 20 mg plus clopidogrel 75 mg tablet is used for prevention of heart attack and stroke. Rosuvastatin is a lipid-lowering medication that blocks the body’s ability to produce LDL cholesterol and improves the level of HDL cholesterol. Clopidogrel is an anti-platelet medication. It prevents the platelets from sticking together and decreases the formation of harmful blood clots.


    Zydus Healthcare Limited had filed a review petition under paragraph 31 of the Drugs (Prices Control) Order, 2013 against notification S.O. No.02(E), dated 01/01/2018 issued by the National Pharmaceutical Pricing Authority (NPPA) fixing the ceiling prices of Rosuvastatin 20mg + Clopidogrel 75mg Capsules.


    In its review petition, Zydus has contended that the price fixed by the NPPA for the new drug formulation rosuvastatin 20mg + clopidogrel 75mg capsule is lower than rosuvastatin 10mg or rosuvastatin 5mg, similar formulations of lower strength, and furnished price charts to substantiate its argument.


    During the examination, NPPA accepted that it had fixed the retail price of Rosuvastatin 20 mg +Clopidogrel 75 mg capsule manufactured by Synokem Pharmaceuticals Limited and marketed by M/s Zydus Healthcare Limited as Rs. 7.80 per capsule vide S.O. 02(E) dated 01.01.2018 as per the decision was taken in 51st Authority Meeting.


    However, on re-examination, it is observed that this price for Rosuvastatin 20 mg + Clopidogrel 75 mg capsule was fixed, which was applicable for Rosuvastatin 20 mg + Aspirin 75 mg and retail price of Rosuvastatin 20 mg + Clopidogrel 75 mg capsule was not fixed by NPPA earlier.


    At the time of examination, the DoP has found merit in the Zydus complaint and asked the national price regulator to refix the rate of the new formulation as per the provisions of the Drug Price Control Order (DPCO) 2013 within a period of one month.


    Giving the decision, DoP stated, “NPPA is hereby directed to refix the retail price of new drug Rosuvastatin 20 mg + Clopidogrel 75 mg as per provision of para 5(1) read with para 9(4) of DPCO, 2013, within a period of one month from the date of issue of the order.”


    Below is the attached judgment for the same
    clopidogrelDepartment of PharmaceuticalsDOPDPCODrug (Price Control) OrderNational Pharmaceutical Pricing AuthorityNPPApetitionRosuvastatinRosuvastatin 20mg + Clopidogrel 75mg CapsulesZydus Healthcare

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok